AR target genes have been established as candidate oncogenes and biomarkers in prostate cancer and in recent years chromatin immunoprecipitation coupled to high-throughputsequencing (ChIP-seq) and expression profiling has enabled an unbiased identification of AR-driven genenetworks. This evidence concerns the gene AR and prostate carcinoma.